-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30

Benzinga·09/18/2026 09:45:22
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and raises the price target from $28 to $30.